Role of radiotherapy in the treatment of CUP syndrome

被引:0
作者
Adamietz, Irenaus A. [1 ,2 ]
Schindler, Natalie [1 ]
机构
[1] Ruhr Univ Bochum, Univ Klin, Marien Hosp Herne, Klin Strahlentherapie & Radioonkol, Holkeskampring 40, D-44625 Herne, Germany
[2] Ruhr Univ Bochum, Univ Klin, St Josef Hosp Bochum, Klin Strahlentherapie & Radioonkol, Bochum, Germany
来源
ONKOLOGE | 2021年 / 27卷 / 07期
关键词
Multimodal treatment; Palliative care; Neoplasms metastasis; Lymphatic metastasis; Neck dissection; LYMPH-NODE METASTASES; LOCALLY ADVANCED HEAD; UNKNOWN PRIMARY; BRAIN METASTASES; NECK-CANCER; RADIATION-THERAPY; PRIMARY TUMORS; MANAGEMENT; DISSECTION; CARCINOMA;
D O I
10.1007/s00761-021-00964-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background CUP (cancer of unknown primary origin) is defined as a heterogeneous group of cancer diseases. The diagnosis of metastatic cancer of unknown primary is associated with uncertainties of both diagnostic and therapeutic nature in everyday oncology practice. Methods Based on literature reviews as well as clinical expertise, the options for radiation treatment in CUP were described. Results Histology, location and extent of tumor manifestations are crucial for planning radiotherapy. Indispensable for targeted and effective radiotherapy are modern imaging techniques for pretherapeutic staging and target volume definition. In combination with surgical and drug approaches, radiotherapy opens up therapeutic possibilities for organ-preserving and curative procedures in axillary and cervical CUP. In palliative situations, radiotherapy offers options for prevention and treatment of disease-associated complications and maintenance of quality of life (e.g., osseous and cerebral metastases). Conclusions The treatment of patients with CUP syndrome presents an interdisciplinary challenge. Radiotherapy offers curative therapy approaches for localized CUP. It is effective in symptomatic metastases.
引用
收藏
页码:663 / 669
页数:7
相关论文
共 33 条
[1]   Percutaneous radiotherapy in tumor treatment. Principles [J].
Adamietz, Irenaeus A. .
ONKOLOGE, 2018, 24 (03) :263-274
[2]   Cancer of unknown primary: Does treatment modality make a difference? [J].
Balaker, Ashley E. ;
Abemayor, Elliot ;
Elashoff, David ;
St John, Maie A. .
LARYNGOSCOPE, 2012, 122 (06) :1279-1282
[3]   Defining risk levels in locally advanced head and neck cancers:: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501) [J].
Bernier, J ;
Cooper, JS ;
Pajak, TF ;
van Glabbeke, M ;
Bourhis, J ;
Forastiere, A ;
Ozsahin, EM ;
Jacobs, JR ;
Jassem, J ;
Ang, KK ;
Lefèbvre, JL .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (10) :843-850
[4]   Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001 [J].
Brown, Paul D. ;
Gondi, Vinai ;
Pugh, Stephanie ;
Tome, Wolfgang A. ;
Wefel, Jeffrey S. ;
Armstrong, Terri S. ;
Bovi, Joseph A. ;
Robinson, Cliff ;
Konski, Andre ;
Khuntia, Deepak ;
Grosshans, David ;
Benzinger, Tammie L. S. ;
Bruner, Deborah ;
Gilbert, Mark R. ;
Roberge, David ;
Kundapur, Vijayananda ;
Devisetty, Kiran ;
Shah, Sunjay ;
Usuki, Kenneth ;
Anderson, Bethany Marie ;
Stea, Baldassarre ;
Yoon, Harold ;
Li, Jing ;
Laack, Nadia N. ;
Kruser, Tim J. ;
Chmura, Steven J. ;
Shi, Wenyin ;
Deshmukh, Snehal ;
Mehta, Minesh P. ;
Kachnic, Lisa A. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (10) :1019-+
[5]   Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C Is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the AR0 95-06 Randomized Phase III Trial [J].
Budach, Volker ;
Stromberger, Carmen ;
Poettgen, Christoph ;
Baumann, Michael ;
Budach, Wilfried ;
Grabenbauer, Gerhard ;
Marnitz, Simone ;
Olze, Heidi ;
Wernecke, Klaus-Dieter ;
Ghadjar, Pirus .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (05) :916-924
[6]   RADIATION THERAPY IN THE MANAGEMENT OF HEAD-AND-NECK CANCER OF UNKNOWN PRIMARY ORIGIN: HOW DOES THE ADDITION OF CONCURRENT CHEMOTHERAPY AFFECT THE THERAPEUTIC RATIO? [J].
Chen, Allen M. ;
Farwell, D. Gregory ;
Lau, Derick H. ;
Li, Bao-Qing ;
Luu, Quang ;
Donald, Paul J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02) :346-352
[7]   Palliative radiotherapy trials for bone metastases: A systematic review [J].
Chow, Edward ;
Harris, Kristin ;
Fan, Grace ;
Tsao, May ;
Sze, Wai M. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) :1423-1436
[8]   Axillary lymph node metastasis in CUP [J].
Fehm, T. ;
Souchon, R. .
ONKOLOGE, 2013, 19 (01) :40-43
[9]   Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].
Fizazi, K. ;
Greco, F. A. ;
Pavlidis, N. ;
Daugaard, G. ;
Oien, K. ;
Pentheroudakis, G. .
ANNALS OF ONCOLOGY, 2015, 26 :V133-V138
[10]  
Flentje M., 2010, BAYER ARZTEBL, V10, P664